Serum ferritin level is associated with liver fibrosis and incident liver-related outcomes independent of HFE genotype in the general population

References

• Fargion S, Valenti L, Fracanzani AL. Beyond hereditary hemochromatosis: new insights into the relationship between iron overload and chronic liver diseases. Dig Liver Dis. 2011;43(2):89–95. doi: 10.1016/j.dld.2010.07.006.
   PubMedGoogle Scholar
• Valenti L, Corradini E, Adams LA, et al. Consensus statement on the definition and classification of metabolic hyperferritinaemia. Nat Rev Endocrinol. 2023;19(5):299–310. doi: 10.1038/s41574-023-00807-6.
   PubMed Web of Science ®Google Scholar
• Adams PC, Reboussin DM, Barton JC, et al. Hemochromatosis and iron-overload screening in a racially diverse population. N Engl J Med. 2005;352(17):1769–1778. doi: 10.1056/NEJMoa041534.
   PubMed Web of Science ®Google Scholar
• McKinnon EJ, Rossi E, Beilby JP, et al. Factors that affect serum levels of ferritin in Australian adults and implications for follow-up. Clin Gastroenterol Hepatol. 2014;12(1):101–108.e4. doi: 10.1016/j.cgh.2013.07.019.
   PubMed Web of Science ®Google Scholar
• Kowdley KV, Belt P, Wilson LA, et al. Serum ferritin is an independent predictor of histologic severity and advanced fibrosis in patients with nonalcoholic fatty liver disease. Hepatology. 2012;55(1):77–85. doi: 10.1002/hep.24706.
   PubMed Web of Science ®Google Scholar
• Chen Q, Gao M, Yang H, et al. Serum ferritin levels are associated with advanced liver fibrosis in treatment-naive autoimmune hepatitis. BMC Gastroenterol. 2022;22(1):23. doi: 10.1186/s12876-022-02098-z.
   PubMed Web of Science ®Google Scholar
• Shan Y, Lambrecht RW, Bonkovsky HL. Association of hepatitis C virus infection with serum iron status: analysis of data from the third national health and nutrition examination survey. Clin Infect Dis. 2005;40(6):834–841. doi: 10.1086/428062.
   PubMed Web of Science ®Google Scholar
• Armandi A, Sanavia T, Younes R, et al. Serum ferritin levels can predict long-term outcomes in patients with metabolic dysfunction-associated steatotic liver disease. Gut. 2024;gutjnl-2023-330815. doi: 10.1136/gutjnl-2023-330815.
   Web of Science ®Google Scholar
• Gleeson D, Evans S, Bradley M, et al. HFE genotypes in decompensated alcoholic liver disease: phenotypic expression and comparison with heavy drinking and with normal controls. Am J Gastroenterol. 2006;101(2):304–310. doi: 10.1111/j.1572-0241.2006.00439.x.
   PubMed Web of Science ®Google Scholar
• Machado MV, Ravasco P, Martins A, et al. Iron homeostasis and H63D mutations in alcoholics with and without liver disease. World J Gastroenterol. 2009;15(1):106–111. doi: 10.3748/wjg.15.106.
   PubMed Web of Science ®Google Scholar
• Lieb M, Palm U, Hock B, et al. Effects of alcohol consumption on iron metabolism. Am J Drug Alcohol Abuse. 2011;37(1):68–73. doi: 10.3109/00952990.2010.535584.
   PubMed Web of Science ®Google Scholar
• Maiwall R, Kumar S, Chaudhary AK, et al. Serum ferritin predicts early mortality in patients with decompensated cirrhosis. J Hepatol. 2014;61(1):43–50. doi: 10.1016/j.jhep.2014.03.027.
   PubMed Web of Science ®Google Scholar
• Meier JA, Bokemeyer A, Cordes F, et al. Serum levels of ferritin and transferrin serve as prognostic factors for mortality and survival in patients with end-stage liver disease: a propensity score-matched cohort study. United European Gastroenterol J. 2020;8(3):332–339. doi: 10.1177/2050640619891283.
   PubMed Web of Science ®Google Scholar
• Distante S, Robson KJH, Graham-Campbell J, et al. The origin and spread of the HFE-C282Y haemochromatosis mutation. Hum Genet. 2004;115(4):269–279. doi: 10.1007/s00439-004-1152-4.
   PubMed Web of Science ®Google Scholar
• Olynyk JK, Ramm GA. Hemochromatosis. N Engl J Med. 2022;387(23):2159–2170. doi: 10.1056/NEJMra2119758.
   PubMed Web of Science ®Google Scholar
• Pilling LC, Tamosauskaite J, Jones G, et al. Common conditions associated with hereditary haemochromatosis genetic variants: cohort study in UK biobank. BMJ. 2019;364:k5222. doi: 10.1136/bmj.k5222.
   PubMedGoogle Scholar
• Ye Q, Qian B-X, Yin W-L, et al. Association between the HFE C282Y, H63D polymorphisms and the risks of non-alcoholic fatty liver disease, liver cirrhosis and hepatocellular carcinoma: an updated systematic review and meta-analysis of 5,758 cases and 14,741 controls. PLoS One. 2016;11(9):e0163423. doi: 10.1371/journal.pone.0163423.
   PubMed Web of Science ®Google Scholar
• Hagström H, Ndegwa N, Jalmeus M, et al. Morbidity, risk of cancer and mortality in 3645 HFE mutations carriers. Liver Int. 2021;41(3):545–553. doi: 10.1111/liv.14792.
   PubMed Web of Science ®Google Scholar
• Atkins JL, Pilling LC, Masoli JAH, et al. Association of hemochromatosis HFE p.C282Y homozygosity with hepatic malignancy. JAMA. 2020;324(20):2048–2057. doi: 10.1001/jama.2020.21566.
   PubMed Web of Science ®Google Scholar
• Heistaro S, editor. Methodology report: health 2000 survey. Helsinki, Finland: Publications of the National Public Health Institute; 2008.
   Google Scholar
• Aromaa S, Koskinen S. Health and functional capacity in Finland: baseline results of the health 2000 health examination survey. National Public Health Institute 2004;Series B. 2004;12:171.
   Google Scholar
• Sund R. Quality of the finnish hospital discharge register: a systematic review. Scand J Public Health. 2012;40(6):505–515. doi: 10.1177/1403494812456637.
   PubMed Web of Science ®Google Scholar
• Hagström H, Adams LA, Allen AM, et al. Administrative coding in electronic health care record-based research of NAFLD: an expert panel consensus statement. Hepatology. 2021;74(1):474–482. doi: 10.1002/hep.31726.
   PubMed Web of Science ®Google Scholar
• Rinella ME, Neuschwander-Tetri BA, Siddiqui MS, et al. AASLD practice guidance on the clinical assessment and management of nonalcoholic fatty liver disease. Hepatology. 2023;77(5):1797–1835. doi: 10.1097/HEP.0000000000000323.
   PubMed Web of Science ®Google Scholar
• Abril-Ulloa V, Flores-Mateo G, Solà-Alberich R, et al. Ferritin levels and risk of metabolic syndrome: meta-analysis of observational studies. BMC Public Health. 2014;14(1):483. doi: 10.1186/1471-2458-14-483.
   PubMedGoogle Scholar
• Tofano RJ, Pescinni-Salzedas LM, Chagas EFB, et al. Association of metabolic syndrome and hyperferritinemia in patients at cardiovascular risk. Diabetes Metab Syndr Obes. 2020;13:3239–3248. doi: 10.2147/DMSO.S271050.
   PubMed Web of Science ®Google Scholar
• Valenti L, Swinkels DW, Burdick L, et al. Serum ferritin levels are associated with vascular damage in patients with nonalcoholic fatty liver disease. Nutr Metab Cardiovasc Dis. 2011;21(8):568–575. doi: 10.1016/j.numecd.2010.01.003.
   PubMed Web of Science ®Google Scholar
• Moris W, Verhaegh P, Jonkers D, et al. Hyperferritinemia in nonalcoholic fatty liver disease: iron accumulation or inflammation? Semin Liver Dis. 2019;39(4):476–482. doi: 10.1055/s-0039-1693114.
   PubMed Web of Science ®Google Scholar
• Adams PC, Barton JC. A diagnostic approach to hyperferritinemia with a non-elevated transferrin saturation. J Hepatol. 2011;55(2):453–458. doi: 10.1016/j.jhep.2011.02.010.
   PubMed Web of Science ®Google Scholar
• Hearnshaw S, Thompson N-P, McGill A. The epidemiology of hyperferritinaemia. World J Gastroenterol. 2006;12(36):5866–5869. doi: 10.3748/wjg.v12.i36.5866.
   PubMed Web of Science ®Google Scholar
• Mantovani A, Csermely A, Castagna A, et al. Associations between higher plasma ferritin and hepcidin levels with liver stiffness in patients with type 2 diabetes: an exploratory study. Liver Int. 2023;43(11):2434–2444. doi: 10.1111/liv.15649.
   PubMedGoogle Scholar
• Ruddell RG, Hoang-Le D, Barwood JM, et al. Ferritin functions as a proinflammatory cytokine via iron-independent protein kinase C zeta/nuclear factor kappaB-regulated signaling in rat hepatic stellate cells. Hepatology. 2009;49(3):887–900. doi: 10.1002/hep.22716.
   PubMed Web of Science ®Google Scholar
• Ali N, Ferrao K, Mehta KJ. Liver iron loading in alcohol-associated liver disease. Am J Pathol. 2022;193(10):1427–1439. doi: 10.1016/j.ajpath.2022.08.010.
   PubMed Web of Science ®Google Scholar
• Dostalikova-Cimburova M, Balusikova K, Kratka K, et al. Role of duodenal iron transporters and hepcidin in patients with alcoholic liver disease. J Cell Mol Med. 2014;18(9):1840–1850. doi: 10.1111/jcmm.12310.
   PubMed Web of Science ®Google Scholar
• Anderson GJ, Vulpe CD. Mammalian iron transport. Cell Mol Life Sci. 2009;66(20):3241–3261. doi: 10.1007/s00018-009-0051-1.
   PubMed Web of Science ®Google Scholar
• Cravo C, Villela-Nogueira CA, Cardoso AC, et al. Relationship of ferritin and hepcidin with disease severity in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus. Liver Int. 2023;43(11):2571–2575. doi: 10.1111/liv.15747.
   PubMedGoogle Scholar
• Kumar S, Wang J, Rani R, et al. Hepatic deficiency of augmenter of liver regeneration exacerbates alcohol-Induced liver injury and promotes fibrosis in mice. PLoS One. 2016;11(1):e0147864. doi: 10.1371/journal.pone.0147864.
   PubMed Web of Science ®Google Scholar
• Ohtake T, Saito H, Hosoki Y, et al. Hepcidin is down-regulated in alcohol loading. Alcoholism Clin Exp Res. 2007;31(s1):S2–S8. doi: 10.1111/j.1530-0277.2006.00279.x.
   PubMedGoogle Scholar